Abstract
Paradigm I: the haematopoietic niche
Early attempts to culture bone marrow revealed that a small fraction of the cells that adhered to culture dishes were not haematopoietic precursors (Fig. 1) . Some investigators were struck by the morphological similarity of the non-haematopoietic cells to the spindle-shaped cells that formed the stroma of marrow [1] [2] [3] [4] . Therefore, they developed the paradigm that the cells formed niches for the propagation of haematopoietic stem cells. The paradigm proved extremely useful in that the confluent cultures of mesenchymal stromal cells (MSCs) were found to be effective feeder layers for the culture of haematopoietic stem cells [5, 6] . The niche role of MSCs was directly demonstrated by the observation that islands of haematopoiesis were formed within ceramic cubes that were seeded with human MSCs and then inserted under the skin of immunodeficient mice [7] . Also, the niche role of MSCs was indirectly supported by clinical trials in which the cells were shown to hasten the recovery of the haematopoietic system after bone marrow transplants [8] .
• 
Early investigators studying cultures of bone marrow were impressed with the facility with which the adherent, spindleshaped cells differentiated into distinct cellular phenotypes. In particular, Friedenstein and others [1] demonstrated that the cells readily became mineralizing cells or chondrocytes both in culture and after implantation in diffusion chambers in vivo. These observations suggested the paradigm that MSCs might repair injured tissues by engraftment and differentiation (Fig. 1). The paradigm had broad implications for medical therapies in part because of the ease with which the cells could be isolated from a small sample of human bone marrow and then rapidly expanded in culture through
30 or more population doublings [9] [10] [11] . In Fig. 1) .
Early observations on engraftment and differentiation

Repair by paradigm II was supported by early observations that local administrations of MSCs improved bone repair [12]. The potential therapeutic implications of the paradigm were expanded by the observation that after systemic infusions of MSCs containing a mutated human gene into irradiated young mice
models for spinal cord injury, local administration of MSCs produced improved motor function but few, if any, of the cells engrafted for prolonged periods or differentiated into neural cells [50, 51]. One initial impression was that the cells formed a scaffold for regeneration of nerve tracts in the cord [51]. A recent study suggested that the therapeutic benefits were explained by anti-inflammatory effects of the cells [52].
Tests of paradigm II with systemic infusion
Tests of paradigm II with systemic infusions of the cells proved problematic. Numerous reports described functional improvements after systemic infusions of MSCs in models for human diseases that included osteogenensis imperfecta
Paradigm III: transient 'quasi-niches'
The accumulating evidence that MSCs could repair injured tissues without significant engraftment and differentiation called for a new paradigm that required re-examination of some of the early observations on cultures of the cells and more detailed examination of their effects in vivo (
Unusual features of MSCs in culture
The early observations that confluent and non-propagating MSCs provided effective feeder layers for cultures of haematopoietic cells were explained in part by the cells secreting paracrine factors [5, 6, 66, 67] . However, the effectiveness of MSCs as feeder layers was not entirely explained by secretion of soluble factors; cell to cell contact was also required for reasons that were not apparent [5, 6] . 
Cross-talk with injured tissues
Although MSCs in culture secreted many cytokines [66, 67] [70, 71] .
Modulation of inflammation in paradigm III
The experiments in which human MSCs were infused intravenously into mice with myocardial infarcts provided a clue to how they enhanced tissue repair. One of the most interesting genes up-regulated in human MSCs that were trapped in the lung after intravenous infusion [62] was tumour necrosis factor (TNF)-␣ stimulated gene/protein-6 (TSG-6) [72, 73] . Extensive previous research demonstrated that TSG-6 had remarkable anti-inflammatory properties in a number of experimental settings, including in both wild-type and transgenic mice [72, 73] (Fig. 2) .
Modulation of apoptosis in paradigm III
Several reports indicated that one of the potential therapeutic effects of MSCs was to decrease apoptosis [77, 78] . Co-culture experiments demonstrated that MSCs decreased apoptosis in two model systems in part by being activated to express stanniocalcin-1(STC-1), a calcium regulatory protein [79] . The effects of STC-1 on apoptosis were apparently explained by its uncoupling of oxidative phosphorylation and suppression of reactive oxygen species [80] . Suppression reactive oxygen species also explains the recent observation the STC-1 has anti-inflammatory properties [81] . [83] [83, 84] . ) Shi and associates [70] [85] .
Modulation of immune reactions
Preliminary observations made in clinical trials to improve bone marrow transplants with MSCs provided an unexpected observation: In a few patients, the MSCs improved the effects of graftversus-host disease [82]. These and related observations led to experiments that demonstrated intravenous infusions of MSCs reduced neurological deficits in the experimental autoimmune encephalitis (EAE) model for multiple sclerosis (see
demonstrated that the immunosuppressive effects of murine MSCs were triggered by the cells being stimulated by interferon-␥ together with any one of three other pro-inflammatory cytokines (TNF-␣, IL-1␣ or IL-1␤). The stimulated MSCs expressed several cytokines and inducible nitric oxide synthase. The chemokines attracted T cells to the MSCs and then the T cells were suppressed by nitric oxide from the MSCs. They subsequently found a marked species difference in that human and monkey MSCs did not synthesize nitric oxide under similar conditions. Instead, the MSCs suppressed T cells by secreting indoleamine 2,3-dioxygenase that depleted tryptophan in the medium or generated toxic concentrations of kynurenine and other metabolites to suppress T cells
Galipeau and associates [86] 
examined the effects of MSCs on activated CD4
ϩ T cells in the EAE model for multiple sclerosis.
They found that the MSCs inhibited activation of the T cells by secreting both CCL2 (monocyte chemotactic protein-1 or MCP-1) and matrix metalloproteinases-9 that cleaved the CCL2 into an antagonistic derivative. The role of the soluble factors was confirmed by the demonstration that conditioned medium from MSCs inhibited activation of CD4 ϩ T cells from EAE mice and that the effects of MSCs were not observed in CCL2 -/-EAE mice. The same laboratory also demonstrated that MSCs can stimulate immune and inflammatory responses. They found that MSCs can crosspresent exogenous antigen and induce an effective CD8
ϩ T-cell immune response [87] . They can also be activated through Tolllike receptors to recruit inflammatory and immune cells [71] . Mahon and associates [88] [62] . [89, 90] 
T cells followed by secretion of transforming growth factor-␤1 and prostaglandin E2 by the MSCs to drive differentiation of T cells to T regulator cells. Uccelli et al. [83] offered a more pleiotrophic account of the effects of MSCs on the immune system. They suggested that
Fig. 2 Effects of human MSCs and recombinant TSG-6 in mice (NOD/scid) with myocardial infarcts (MI). (A) Schematic illustrating
MSCs produced a variety of effects such as (1) decreased proliferation, cytotoxicity and cytokine production by NK cells; (2) impaired maturation and antigen presentation by dendritic cells; (3) decreased proliferation of T cells and impaired T helper cells and (4) decreased proliferation and antibody production by B cells. At the moment, it is not clear which of the proposals best accounts for the immune modulatory effects of MSCs in vivo.
Paradigm III and the similarities to paradigm I
The experiments in which MSCs enhance tissue repair without significant engraftment suggest that there is a complex series of interactions between the MSCs and the injured tissues. One of the key interactions is a sequence in which TNF-␣ and other signals from injured tissues activate the MSCs to secrete TSG-6, STC-1 and probably other soluble factors that decrease the production of TNF-␣ and other inflammatory signals from the injured tissues (Fig. 3). In effect, the MSCs introduce a negative feedback loop into excessive responses by tissues that frequently occur in injuries not accompanied by invading organisms. Such excessive inflammatory and immune responses are now recognized to contribute to the pathoetiology of many diseases, including diabetes and artherosclerosis
. Secretion of soluble factors probably explains the therapeutic effects of intravenous infusion of MSCs or conditioned medium from MSC cultures in some animal models. However, some of the therapeutic effects, such as in models for immune diseases, may require direct cell-to-cell contact between MSCs and target cells. Also, in addition to modulating inflammatory/immune reactions, MSCs may enhance repair of tissues by stimulating the proliferation and differentiation of tissue endogenous stem/progenitor cells as was observed with infusion of MSCs into the hippocampus of mice [48]. Many of the effects of MSCs on tissue repair are transient 'hit and run' events (paradigm III) but they have some similarities to the ability of the cells to provide a niche for haematopoietic cells (paradigm I).
Conclusions/perspectives
Are MSCs pericytes?
Recent reports have provided convincing data for earlier suggestions (see [9] ) that MSCs share many of the features of pericytes [91] [92] [93] ; cells that have fascinated investigators since they were first described by Rouget in 1873 (see [94] 
